GlassScriptPhysician profile
Bryan G Wernick
NPI 1174578322
$5,908.50
in general payments reported to CMS, 2019-2025
25 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $42.99 · 2021: $411 · 2022: $1,808 · 2023: $167 · 2024: $751 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599 · Travel and Lodging: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.06 |
| Travel and Lodging | $620.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,417.20 | 2021-2025 | Eterna, Proclaim |
| Medtronic USA, INC. | $984.57 | 2019-2020 | |
| Stryker Corporation | $802.67 | 2025 | Mild Device Kit, Optablate, Spinejack |
| Medtronic Vascular, INC. | $404.33 | 2019 | |
| Spr Therapeutics, INC | $319.76 | 2024-2025 | Sprint Pns System |
| Medtronic, INC. | $225.23 | 2022-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $170.05 | 2021-2025 | Wavewriter Alpha Prime 16, G4 Rf Generator |
| Abbvie INC. | $142.88 | 2023-2025 | Botox |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.75 | 2023-2025 | Relistor |
| Saluda Medical Americas, INC. | $55.75 | 2023-2025 | Evoke, Evoke Scs |
| Qol Medical, LLC | $37.95 | 2024 | Sucraid |
| Collegium Pharmaceutical, INC. | $32.69 | 2023-2024 | Belbuca |
| Bioventus LLC | $23.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.62 | 2024 | Entyvio |
| Si-Bone, INC. | $22.40 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.24 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Pfizer INC. | $18.97 | 2025 | |
| Globus Medical, INC. | $17.06 | 2025 | Senza |
| Convatec INC. | $16.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.37 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.80 | 2025 | |
| Depuy Synthes Sales INC. | $15.54 | 2019 | |
| Curonix LLC | $14.49 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $13.90 | 2019 | |
| Lilly USA, LLC | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Wernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.